PEG drugs: an overview
2001; Elsevier BV; Volume: 74; Issue: 1-3 Linguagem: Inglês
10.1016/s0168-3659(01)00331-5
ISSN1873-4995
Autores Tópico(s)Nanoparticle-Based Drug Delivery
ResumoNo low molecular weight ( 20 000), and especially employing PEG 40 000 which is estimated to have a plasma circulating half life of approximately 8–9 h in the mouse. This recent resuscitation of small organic molecule delivery by high molecular weight PEG conjugates was founded on meaningful in vivo testing using established tumor models, and has led to a clinical candidate. Recent applications of high molecular weight PEG prodrug strategies to amino containing drugs are also detailed, and potential applications to proteins are proposed.
Referência(s)